Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT

Abstract Background Bone marrow toxicity in advanced prostate cancer patients who receive [177Lu]Lu-PSMA-617 is a well-known concern. In early stage patients; e.g. low volume metastatic hormone sensitive prostate cancer (mHSPC) patients, prevention of late bone marrow toxicity is even more crucial d...

Full description

Bibliographic Details
Published in:EJNMMI Physics
Main Authors: Dagmar Grob, Bastiaan M. Privé, Constantijn H. J. Muselaers, Niven Mehra, James Nagarajah, Mark W. Konijnenberg, Steffie M. B. Peters
Format: Article
Language:English
Published: SpringerOpen 2024-04-01
Subjects:
Bone marrow dosimetry
Absorbed dose
Radionuclide therapy
177-Lu-PSMA
Online Access:https://doi.org/10.1186/s40658-024-00636-0

Internet

https://doi.org/10.1186/s40658-024-00636-0

Similar Items